University Hospital Olomouc
University Hospital Olomouc
Olomouc, Czechia8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 3 | 2026-09-25 | NCT07276399 | |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06208150 | |
| Evaluation of the Safety and Efficacy of Parecoxib in Patients With Subarachnoid Hemorrhage | Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Recruiting | Phase 2 | 2026-08-21 | NCT06579274 | |
| IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, disease, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-08-14 | NCT06713837 | |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Active, not recruiting | Phase 3 | 2026-07-17 | NCT04603495 | |
| Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2025-10-03 | NCT05840211 | |
| Rectal Cancer CTC Trial | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Cells, Circulating, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Recruiting | Not applicable | 2025-09-26 | NCT07194616 | |
| International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Not applicable | 2024-07-08 | NCT03386734 |